284 related articles for article (PubMed ID: 17457345)
1. Immune evasion by Kaposi's sarcoma-associated herpesvirus.
Coscoy L
Nat Rev Immunol; 2007 May; 7(5):391-401. PubMed ID: 17457345
[TBL] [Abstract][Full Text] [Related]
2. Molecular virology of Kaposi's sarcoma-associated herpesvirus.
Moore PS; Chang Y
Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):499-516. PubMed ID: 11313008
[TBL] [Abstract][Full Text] [Related]
3. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
4. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis.
Viejo-Borbolla A; Schulz TF
AIDS Rev; 2003; 5(4):222-9. PubMed ID: 15012001
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?
Moore PS; Chang Y
Annu Rev Microbiol; 2003; 57():609-39. PubMed ID: 14527293
[TBL] [Abstract][Full Text] [Related]
6. Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease.
Abe Y; Matsubara D; Gatanaga H; Oka S; Kimura S; Sasao Y; Saitoh K; Fujii T; Sato Y; Sata T; Katano H
Pathol Int; 2006 Oct; 56(10):617-24. PubMed ID: 16984619
[TBL] [Abstract][Full Text] [Related]
7. The pleiotropic effects of Kaposi's sarcoma herpesvirus.
Schulz TF
J Pathol; 2006 Jan; 208(2):187-98. PubMed ID: 16362980
[TBL] [Abstract][Full Text] [Related]
8. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis.
Liang C; Lee JS; Jung JU
Semin Cancer Biol; 2008 Dec; 18(6):423-36. PubMed ID: 18948197
[TBL] [Abstract][Full Text] [Related]
9. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma.
Sirianni MC; Vincenzi L; Topino S; Giovannetti A; Mazzetta F; Libi F; Scaramuzzi D; Andreoni M; Pinter E; Baccarini S; Rezza G; Monini P; Ensoli B
Eur J Immunol; 2002 Oct; 32(10):2711-20. PubMed ID: 12355422
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs of Kaposi's sarcoma-associated herpes virus.
Ganem D; Ziegelbauer J
Semin Cancer Biol; 2008 Dec; 18(6):437-40. PubMed ID: 19013245
[No Abstract] [Full Text] [Related]
11. Signal transduction targets in Kaposi's sarcoma.
Sullivan R; Dezube BJ; Koon HB
Curr Opin Oncol; 2006 Sep; 18(5):456-62. PubMed ID: 16894293
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals.
Okroj M; Spiller OB; Korodi Z; Tedeschi R; Dillner J; Blom AM
Vaccine; 2007 Nov; 25(48):8102-9. PubMed ID: 17964697
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion by Kaposi's sarcoma-associated herpesvirus.
Lee HR; Lee S; Chaudhary PM; Gill P; Jung JU
Future Microbiol; 2010 Sep; 5(9):1349-65. PubMed ID: 20860481
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cell signaling pathways by Kaposi's sarcoma-associated herpesvirus (KSHVHHV-8).
Damania B
Cell Biochem Biophys; 2004; 40(3):305-22. PubMed ID: 15211030
[TBL] [Abstract][Full Text] [Related]
15. The contribution of systems biology and reverse genetics to the understanding of Kaposi's sarcoma-associated herpesvirus pathogenesis in endothelial cells.
Stürzl M; Konrad A; Alkharsah KR; Jochmann R; Thurau M; Marquardt G; Schulz TF
Thromb Haemost; 2009 Dec; 102(6):1117-34. PubMed ID: 19967142
[TBL] [Abstract][Full Text] [Related]
16. Interplay between Kaposi's sarcoma-associated herpesvirus and the innate immune system.
Brulois K; Jung JU
Cytokine Growth Factor Rev; 2014 Oct; 25(5):597-609. PubMed ID: 25037686
[TBL] [Abstract][Full Text] [Related]
17. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes.
Stebbing J; Bourboulia D; Johnson M; Henderson S; Williams I; Wilder N; Tyrer M; Youle M; Imami N; Kobu T; Kuon W; Sieper J; Gotch F; Boshoff C
J Virol; 2003 Apr; 77(7):4306-14. PubMed ID: 12634388
[TBL] [Abstract][Full Text] [Related]
18. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins.
Woodberry T; Suscovich TJ; Henry LM; Martin JN; Dollard S; O'Connor PG; Davis JK; Osmond D; Lee TH; Kedes DH; Khatri A; Lee J; Walker BD; Scadden DT; Brander C
J Infect Dis; 2005 Aug; 192(4):622-9. PubMed ID: 16028131
[TBL] [Abstract][Full Text] [Related]
19. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus.
Aresté C; Blackbourn DJ
Trends Microbiol; 2009 Mar; 17(3):119-29. PubMed ID: 19230674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
